-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
FibroGen (NASDAQ:FGEN) Given New $14.00 Price Target at Cowen
FibroGen (NASDAQ:FGEN) Given New $14.00 Price Target at Cowen
FibroGen (NASDAQ:FGEN – Get Rating) had its price target raised by Cowen to $14.00 in a research report report published on Monday morning, Stock Target Advisor reports.
Several other analysts have also recently commented on the stock. StockNews.com cut shares of FibroGen from a buy rating to a hold rating in a report on Wednesday, August 10th. The Goldman Sachs Group reduced their target price on shares of FibroGen from $9.00 to $8.00 and set a sell rating for the company in a research note on Tuesday, May 24th.
Get FibroGen alerts:FibroGen Price Performance
Shares of FGEN opened at $14.59 on Monday. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -6.16 and a beta of 0.87. The company has a 50-day moving average of $11.91 and a two-hundred day moving average of $11.98. FibroGen has a one year low of $7.81 and a one year high of $16.91.
FibroGen (NASDAQ:FGEN – Get Rating) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.16. The business had revenue of $29.81 million during the quarter, compared to analysts' expectations of $36.15 million. FibroGen had a negative net margin of 83.64% and a negative return on equity of 100.51%. The firm's quarterly revenue was up 22.3% compared to the same quarter last year. During the same period last year, the company posted ($1.45) earnings per share. Analysts anticipate that FibroGen will post -3 earnings per share for the current year.Institutional Trading of FibroGen
A number of institutional investors have recently added to or reduced their stakes in FGEN. Point72 Asset Management L.P. lifted its stake in FibroGen by 235.9% in the fourth quarter. Point72 Asset Management L.P. now owns 3,732,594 shares of the biopharmaceutical company's stock valued at $52,630,000 after acquiring an additional 2,621,494 shares during the last quarter. Soleus Capital Management L.P. bought a new position in shares of FibroGen in the fourth quarter valued at approximately $21,862,000. Federated Hermes Inc. raised its position in shares of FibroGen by 84.1% in the first quarter. Federated Hermes Inc. now owns 2,395,883 shares of the biopharmaceutical company's stock valued at $28,799,000 after purchasing an additional 1,094,403 shares during the period. First Trust Advisors LP raised its position in shares of FibroGen by 24.8% in the fourth quarter. First Trust Advisors LP now owns 5,317,613 shares of the biopharmaceutical company's stock valued at $74,978,000 after purchasing an additional 1,055,536 shares during the period. Finally, Assenagon Asset Management S.A. increased its position in FibroGen by 333.0% during the second quarter. Assenagon Asset Management S.A. now owns 972,901 shares of the biopharmaceutical company's stock worth $10,274,000 after acquiring an additional 748,230 shares during the period. 77.35% of the stock is currently owned by institutional investors and hedge funds.
FibroGen Company Profile
(Get Rating)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
See Also
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- 3 Blowout Earnings Reports That Could Mark Turning Points
- Will CrowdStrike Extend Its Streak Of Topping Earnings Views?
- Skyworks Solutions Is Worth A Look At These Prices
- 3 Stocks Set to Lead the Nasdaq Bull Market
- MarketBeat Podcast: ESG – Profitably Invest Your Values
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
FibroGen (NASDAQ:FGEN – Get Rating) had its price target raised by Cowen to $14.00 in a research report report published on Monday morning, Stock Target Advisor reports.
据Stock Target Advisor报道,考恩在周一上午发布的一份研究报告中将FibroGen(纳斯达克:FDEN-GET评级)的目标价上调至14.00美元。
Several other analysts have also recently commented on the stock. StockNews.com cut shares of FibroGen from a buy rating to a hold rating in a report on Wednesday, August 10th. The Goldman Sachs Group reduced their target price on shares of FibroGen from $9.00 to $8.00 and set a sell rating for the company in a research note on Tuesday, May 24th.
其他几位分析师最近也对该股发表了评论。在8月10日星期三的一份报告中,StockNews.com将FibroGen的股票评级从买入下调至持有。5月24日,高盛夫妇将FibroGen的股票目标价从9.00美元下调至8.00美元,并在周二的一份研究报告中为该公司设定了卖出评级。
FibroGen Price Performance
FibroGen性价比
Shares of FGEN opened at $14.59 on Monday. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -6.16 and a beta of 0.87. The company has a 50-day moving average of $11.91 and a two-hundred day moving average of $11.98. FibroGen has a one year low of $7.81 and a one year high of $16.91.
周一,fgen的股价开盘报14.59美元。该股市值为13.7亿美元,市盈率为-6.16倍,贝塔系数为0.87。该公司的50日移动均线切入位在11.91美元,200日移动均线切入位在11.98美元。FibroGen的一年低点为7.81美元,一年高位为16.91美元。
Institutional Trading of FibroGen
FibroGen的机构交易
A number of institutional investors have recently added to or reduced their stakes in FGEN. Point72 Asset Management L.P. lifted its stake in FibroGen by 235.9% in the fourth quarter. Point72 Asset Management L.P. now owns 3,732,594 shares of the biopharmaceutical company's stock valued at $52,630,000 after acquiring an additional 2,621,494 shares during the last quarter. Soleus Capital Management L.P. bought a new position in shares of FibroGen in the fourth quarter valued at approximately $21,862,000. Federated Hermes Inc. raised its position in shares of FibroGen by 84.1% in the first quarter. Federated Hermes Inc. now owns 2,395,883 shares of the biopharmaceutical company's stock valued at $28,799,000 after purchasing an additional 1,094,403 shares during the period. First Trust Advisors LP raised its position in shares of FibroGen by 24.8% in the fourth quarter. First Trust Advisors LP now owns 5,317,613 shares of the biopharmaceutical company's stock valued at $74,978,000 after purchasing an additional 1,055,536 shares during the period. Finally, Assenagon Asset Management S.A. increased its position in FibroGen by 333.0% during the second quarter. Assenagon Asset Management S.A. now owns 972,901 shares of the biopharmaceutical company's stock worth $10,274,000 after acquiring an additional 748,230 shares during the period. 77.35% of the stock is currently owned by institutional investors and hedge funds.
一些机构投资者最近增持或减持了fgen的股份。Point72 Asset Management L.P.在第四季度将其在FibroGen的持股比例提高了235.9%。Point72 Asset Management L.P.在上个季度额外收购了2,621,494股后,现在拥有这家生物制药公司3732,594股股票,价值52,630,000美元。Soleus Capital Management L.P.在第四季度购买了FibroGen的新头寸,价值约21,862,000美元。联合爱马仕公司在第一季度将其在FibroGen的股票持仓量提高了84.1%。联合爱马仕公司目前持有这家生物制药公司2,395,883股股票,价值28,799,000美元,在此期间又购买了1,094,403股。First Trust Advisors LP在第四季度将其在FibroGen股票的头寸提高了24.8%。First Trust Advisors LP现在拥有这家生物制药公司5,317,613股股票,价值74,978,000美元,在此期间又购买了1,055,536股。最后,Assenagon Asset Management S.A.在第二季度将其在FibroGen的头寸增加了333.0%。Assenagon Asset Management S.A.在此期间额外收购了748,230股票,现在拥有972,901股这家生物制药公司的股票,价值10,274,000美元。77.35%的股票目前由机构投资者和对冲基金持有。
FibroGen Company Profile
FibroGen公司简介
(Get Rating)
(获取评级)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
FibroGen,Inc.是一家生物制药公司,发现、开发和商业化治疗严重未得到满足的医疗需求的疗法。该公司正在开发一种口服低氧诱导因子Pro羟基酶小分子抑制剂roxadustat,该药已在美国、欧洲、中国和日本完成了治疗慢性肾脏疾病贫血的第三阶段临床开发,并在中国完成了治疗与骨髓增生异常综合征相关的贫血的第二/第三阶段临床开发。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- 3 Blowout Earnings Reports That Could Mark Turning Points
- Will CrowdStrike Extend Its Streak Of Topping Earnings Views?
- Skyworks Solutions Is Worth A Look At These Prices
- 3 Stocks Set to Lead the Nasdaq Bull Market
- MarketBeat Podcast: ESG – Profitably Invest Your Values
- 免费获取StockNews.com关于FibroGen的研究报告(Fgen)
- 3份井喷式收益报告可能标志着转折点
- CrowdStrike是否会延续其盈利排行榜榜首的势头?
- Skyworks Solutions值得看看这些价格
- 3只股票将引领纳斯达克牛市
- MarketBeat播客:ESG--有利可图地投资你的价值
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受FibroGen Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对FibroGen和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧